Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tuberculosis vaccine development.

T Mark Doherty1, Peter Andersen

  • 1Department of Tuberculosis Immunology, Statens Serum Institut, Copenhagen, Denmark. tmd@ssi.dk

Current Opinion in Pulmonary Medicine
|May 1, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multiplexed targeted mRNA profiling of alcohol-related liver disease reveals stage-specific dysregulation of signaling pathways.

Molecular biology reports·2026
Same author

Liver stiffness dynamics in European populations (LiverScreen): a longitudinal, multicentre, prospective, population-based cohort study.

The lancet. Gastroenterology & hepatology·2026
Same author

Paired Liver Biopsies vs Noninvasive Tests as Surrogate Endpoints for Clinical Trials in Metabolic and Alcohol-Related Liver Disease and Alcohol-Related Liver Disease.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

Reliability of Hepatic Steatosis Quantification by Controlled Attenuation Parameter in Steatotic Liver Disease.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

Prevalence of liver fibrosis in the general population (the LiverScreen project): a multinational European cohort study.

Lancet (London, England)·2026
Same author

Fibrosis activity <i>vs</i>. disease stage: Complementary and independent predictors of outcomes in alcohol-related liver disease.

JHEP reports : innovation in hepatology·2026
Same journal

Toward precision imaging in interstitial lung disease: advances in quantitative imaging and artificial intelligence.

Current opinion in pulmonary medicine·2026
Same journal

Oxygen therapy in interstitial lung disease - navigating benefit and burden.

Current opinion in pulmonary medicine·2026
Same journal

Preclinical and clinical advances in pulmonary hypertension associated with systemic sclerosis.

Current opinion in pulmonary medicine·2026
Same journal

Advancing lung transplantation: current challenges and future directions.

Current opinion in pulmonary medicine·2026
Same journal

Association between upper airway obstruction and pulmonary hypertension in children with Down syndrome.

Current opinion in pulmonary medicine·2026
Same journal

Molecular mechanisms of environmental risk factors for interstitial lung disease.

Current opinion in pulmonary medicine·2026
See all related articles

Genomics and proteomics accelerate tuberculosis vaccine development. Promising new TB vaccines are now advancing to clinical trials, aided by better animal models and immunity insights.

Area of Science:

  • Biotechnology
  • Immunology
  • Infectious Diseases

Background:

  • Genomics and proteomics have revolutionized biological research.
  • Tuberculosis (TB) vaccine development has been significantly impacted by these advancements.
  • Previous timelines predicted a decade delay for TB vaccine clinical trials.

Purpose of the Study:

  • To highlight the impact of genomics and proteomics on TB vaccine research.
  • To report the accelerated timeline for TB vaccine clinical trials.
  • To describe the shift in research focus towards selecting optimal TB vaccine candidates.

Main Methods:

  • Leveraging advancements in genomics and proteomics for TB research.
  • Utilizing improved animal models for vaccine candidate evaluation.

Related Experiment Videos

  • Applying increased understanding of TB immunity to guide vaccine selection.

    • Main Results:

    • The first clinical trials for new TB vaccines are imminent.
    • Research focus has shifted from vaccine development to selection.
    • Improved animal models and immunity knowledge facilitate candidate selection.

    Conclusions:

    • Genomics and proteomics are rapidly advancing TB vaccine development.
    • New TB vaccines are progressing to human trials much sooner than anticipated.
    • Enhanced research tools and knowledge are crucial for selecting effective TB vaccines.